| Chemical Properties | Off White Solid |
| Uses | A metabolite of Allopurinol. |
| Uses | 4,6-Dihydroxy-1H-pyrazolo[3,4-d]pyrimidine is an inhibitor to study the specificity and kinetics of xanthine oxidase. It is also used as an anti-inflammatory agent via inhibition of xanthine oxidase. |
| Uses | Oxypurinol, an allopurinol metabolite, is used as an inhibitor to study the specificity and kinetics of of xanthine oxidase(s). Oxypurinol is also used as an anti-inflammatory agent via inhibition of xanthine oxidase. |
| Definition | ChEBI: A pyrazolopyrimidine that is 4,5,6,7-tetrahydro-H-pyrazolo[3,4-d]pyrimidine substituted by oxo groups at positions 4 and 6. |
| Biological Activity | oxipurinol is a xanthine oxidoreductase inhibitor.xanthine oxidoreductase (xo), a complex molybdoflavoenzyme present in milk and many other tissues, has been studied for many years. xo is generally recognized as a critical enzyme in purine catabolism. |
| Biochem/physiol Actions | An allopurinol metabolite. |
| in vitro | allopurinol could be rapidly oxidized by xo to its active metabolite oxypurinol (both isosteres of hypoxanthine and xanthine, respectively), which also could inhibit xo. oxypurinol was identified as a noncompetitive inhibitor of xo; the formation of this compound was reported to be responsible for much of the pharmacological activity of allopurinol. moreover, both allopurinol and oxypurinol showed free radical scavenging effects in isolated hearts, and exerted cardioprotective effects despite no detectable xo activities [1]. |
| in vivo | animal study found that in the vasculature of hypercholesterolemic rabbits, oxypurinol treatment led to a decrease in vascular free radical production [1]. |
| references | [1] p. pacher, a. nivorozhkin and c. szabó. therapeutic effects of xanthine oxidase inhibitors: renaissance half a century after the discovery of allopurinol. pharmacological reviews 58(1), 87-114 (2006).[2] day ro, graham gg, hicks m, mclachlan aj, stocker sl, williams km. clinical pharmacokinetics and pharmacodynamics of allopurinol and oxypurinol. clin pharmacokinet. 2007;46(8):623-44. |
日本语
한국어
Français
Deutsch
España
Türkiye